CSIMarket
 


Kura Oncology Inc   (KURA)
Other Ticker:  
 

Kura Oncology Inc 's Leverage Ratio

KURA's quarterly Leverage Ratio and Total Liabilities, Equity growth


Due to net new borrowings of 14.2%, Leverage Ratio fell to 0.08, below the Kura Oncology Inc 's average Leverage Ratio.

Within Major Pharmaceutical Preparations industry in the third quarter 2023, 18 other companies have achieved lower Leverage Ratio than Kura Oncology Inc in the III Quarter 2023. While Leverage Ratio total ranking has improved so far in the third quarter 2023 to 60, from total ranking in the second quarter 2023 at 89 .

Explain Leverage Ratio?
Who are KURA Customers?
What are KURA´s Total Liabilities?


KURA Leverage Ratio (Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Equity Change 2.46 % 2.27 % -17.02 % -17.04 % -21.38 %
Y / Y Total Liabilities Change 55.33 % 94.86 % 65.9 % 36.5 % 3.15 %
Leverage Ratio MRQ 0.08 0.07 0.07 0.07 0.05
KURA's Total Ranking # 60 # 89 # 133 # 27 # 82
Seq. Equity Change -6.47 % 16.32 % -5.97 % 0.16 % -6.65 %
Seq. Total Liabilities Change 14.2 % 18.17 % -15.11 % 35.59 % 43.27 %



Leverage Ratio third quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 19
Healthcare Sector # 36
Overall Market # 60


Leverage Ratio Statistics
High Average Low
0.27 0.1 0.03
(Jun 30 2017)   (Mar 31 2022)




Financial Statements
Kura Oncology Inc 's Equity $ 430 Millions Visit KURA's Balance sheet
Kura Oncology Inc 's Total Liabilities $ 36 Millions Visit KURA's Balance sheet
Source of KURA's Sales Visit KURA's Sales by Geography


Cumulative Kura Oncology Inc 's Leverage Ratio

KURA's Leverage Ratio for the trailling 12 Months

KURA Leverage Ratio

(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Equity TTM Growth 2.46 % 2.27 % -17.02 % -17.04 % -21.38 %
Y / Y Total Liabilities TTM Growth 55.33 % 94.86 % 65.9 % 36.5 % 3.15 %
Leverage Ratio TTM 0.07 0.07 0.06 0.05 0.04
Total Ranking TTM # 129 # 2 # 90 # 18 # 59
Seq. Equity TTM Growth -6.47 % 16.32 % -5.97 % 0.16 % -6.65 %
Seq. Total Liabilities TTM Growth 14.2 % 18.17 % -15.11 % 35.59 % 43.27 %


On the trailing twelve months basis Despite of the net new borrowings of 14.2% during the twelve months period ending in III Quarter 2023 Kura Oncology Inc has managed to unchanged Leverage Ratio in the III Quarter 2023 to 0.07, below Kura Oncology Inc 's average Leverage Ratio.
Leverage Ratio is the average cumulative value over the last four quarters.

Among companies in the Major Pharmaceutical Preparations industry 50, during the past 12 months, other companies have achieved lower Leverage Ratio than Kura Oncology Inc . While Leverage Ratio total ranking has deteriorated during the twelve months ending in the III Quarter 2023, compared to the prior period, from 2 to 129.

Explain Leverage Ratio?
Who are KURA Customers?
What are KURA´s Total Liabilities?

TTM Leverage Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 51
Healthcare Sector # 69
Within the Market # 129


trailing twelve months Leverage Ratio Statistics
High Average Low
0.2 0.1 0.05
(Dec 31 2017)   (Mar 31 2022)




Companies with similar Leverage Ratio in the quarter ending Sep 30 2023, within Major Pharmaceutical Preparations Industry Leverage RatioSep 30 2023 MRQ Total LiabilitiesSep 30 2023 MRQ Equity
Repare Therapeutics Inc   0.23 $ 53.039  Millions$ 233.368  Millions
Adial Pharmaceuticals Inc   0.23 $ 0.528  Millions$ 2.339  Millions
Ainos Inc   0.22 $ 6.179  Millions$ 27.681  Millions
Frequency Therapeutics Inc   0.22 $ 8.185  Millions$ 36.737  Millions
United Therapeutics Corporation  0.22 $ 1,270.900  Millions$ 5,712.100  Millions
Ovid Therapeutics Inc   0.22 $ 22.512  Millions$ 101.292  Millions
Procyon Corporation  0.22 $ 0.568  Millions$ 2.595  Millions
Sanofi  0.22 $ 18,148.480  Millions$ 83,275.360  Millions
Zentalis Pharmaceuticals Inc   0.22 $ 103.947  Millions$ 481.897  Millions
Aurinia Pharmaceuticals Inc   0.21 $ 84.230  Millions$ 391.877  Millions
Benitec Biopharma Inc   0.21 $ 4.745  Millions$ 22.308  Millions
Synlogic Inc   0.21 $ 9.144  Millions$ 43.404  Millions
Prothena Corporation Public Limited Company  0.21 $ 129.693  Millions$ 617.227  Millions
Schrodinger Inc   0.21 $ 117.847  Millions$ 563.581  Millions
Adicet Bio Inc   0.20 $ 38.580  Millions$ 194.677  Millions
Aldeyra Therapeutics Inc   0.20 $ 24.209  Millions$ 123.008  Millions
Intra cellular Therapies Inc   0.19 $ 116.983  Millions$ 600.681  Millions
Mirati Therapeutics Inc   0.19 $ 183.243  Millions$ 946.465  Millions
Kiniksa Pharmaceuticals ltd   0.19 $ 77.936  Millions$ 405.127  Millions
Nanoviricides inc   0.19 $ 2.448  Millions$ 12.969  Millions
Spruce Biosciences Inc   0.19 $ 15.988  Millions$ 85.381  Millions
Catalyst Pharmaceuticals Inc   0.19 $ 64.663  Millions$ 348.548  Millions
Forte Biosciences Inc   0.18 $ 7.471  Millions$ 40.408  Millions
Zai Lab Limited  0.18 $ 162.715  Millions$ 880.979  Millions
Vistagen Therapeutics Inc   0.18 $ 6.551  Millions$ 35.645  Millions
Cyclerion Therapeutics Inc   0.18 $ 2.341  Millions$ 12.873  Millions
Aadi Bioscience Inc   0.18 $ 21.463  Millions$ 118.196  Millions
Compass Pathways Plc  0.18 $ 45.778  Millions$ 253.255  Millions
Coya Therapeutics Inc   0.18 $ 1.807  Millions$ 10.089  Millions
Cogent Biosciences Inc   0.17 $ 52.548  Millions$ 302.898  Millions

Date modified: 2023-11-03T16:25:35+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com